Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The AI-focused biotech insitro is advancing a new idea to potentially treat ALS, one of the most intractable and brutal diseases. The South San Francisco
LONDON — Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on AI’s future in drug discovery.
What started as two CEOs eating tacos and talking biotech led to a merger and a new company. The epigenetic editing startup Chroma Medicine and
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
The transition team for President-elect Donald Trump was still searching for its next National Institutes of Health director as recently as last week, multiple sources
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Can Ken Mulvany save BenevolentAI? About a decade ago, Mulvany helped found the company as part of the first generation of AI-focused biotech startups. It